Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Retreatment"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 53
Tytuł:
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).
Autorzy:
Deshayes E; Nuclear Medicine Department, Montpellier Cancer Institute (ICM), University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France. .; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, University of Montpellier, Montpellier, France. .
Assenat E; Medical Oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.; Medical Oncology Department, CHU Montpellier, University of Montpellier, Montpellier, France.
Meignant L; Clinical Research and Innovation Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Bardiès M; Nuclear Medicine Department, Montpellier Cancer Institute (ICM), University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, University of Montpellier, Montpellier, France.
Santoro L; Nuclear Medicine Department, Montpellier Cancer Institute (ICM), University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, University of Montpellier, Montpellier, France.
Gourgou S; Biometrics Unit, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Dec 22; Vol. 22 (1), pp. 1346. Date of Electronic Publication: 2022 Dec 22.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Neuroendocrine Tumors*/pathology
Organometallic Compounds*/adverse effects
Humans ; Quality of Life ; Prospective Studies ; Octreotide ; Retreatment
SCR Disease Name:
Gastro-enteropancreatic neuroendocrine tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.
Autorzy:
Atrash S; Levine Cancer Institute, Charlotte, NC, USA.
Thompson-Leduc P; Analysis Group, Inc, 1190 avenue des Canadiens-de-Montréal, Deloitte Tower, Suite 1500, Montreal, QC, H3B 0G7, Canada. .
Tai MH; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Kaila S; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Gray K; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Ghelerter I; Analysis Group, Inc, 1190 avenue des Canadiens-de-Montréal, Deloitte Tower, Suite 1500, Montreal, QC, H3B 0G7, Canada.
Lafeuille MH; Analysis Group, Inc, 1190 avenue des Canadiens-de-Montréal, Deloitte Tower, Suite 1500, Montreal, QC, H3B 0G7, Canada.
Lefebvre P; Analysis Group, Inc, 1190 avenue des Canadiens-de-Montréal, Deloitte Tower, Suite 1500, Montreal, QC, H3B 0G7, Canada.
Rossi A; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Nov 12; Vol. 21 (1), pp. 1207. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents/*therapeutic use
Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Medical Records ; Middle Aged ; Progression-Free Survival ; Retreatment ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Autorzy:
Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK. .
Choueiri TK; Dana-Farber Cancer Center, Boston, MA, USA.
Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonasch E; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pal S; City of Hope National Medical Center, Duarte, CA, USA.
Tannir NM; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Signoretti S; Brigham and Women's Hospital, Boston, MA, USA.
Kaldate R; Exelixis, Inc, Alameda, CA, USA.
Scheffold C; Exelixis, Inc, Alameda, CA, USA.
Wang E; Exelixis, Inc, Alameda, CA, USA.
Aftab DT; Exelixis, Inc, Alameda, CA, USA.
Escudier B; Gustave-Roussy, Villejuif, France.
George DJ; Duke Cancer Institute, Durham, NC, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Aug 07; Vol. 21 (1), pp. 904. Date of Electronic Publication: 2021 Aug 07.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Anilides/*therapeutic use
Biomarkers, Tumor/*blood
Carcinoma, Renal Cell/*blood
Carcinoma, Renal Cell/*drug therapy
Everolimus/*therapeutic use
Kidney Neoplasms/*blood
Kidney Neoplasms/*drug therapy
Pyridines/*therapeutic use
Anilides/administration & dosage ; Anilides/adverse effects ; Carcinoma, Renal Cell/diagnosis ; Carcinoma, Renal Cell/mortality ; Everolimus/administration & dosage ; Everolimus/adverse effects ; Humans ; Kaplan-Meier Estimate ; Kidney Neoplasms/diagnosis ; Kidney Neoplasms/mortality ; Prognosis ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation.
Autorzy:
Mishra G; Gastroenterology, Monash Health, Melbourne, Australia.
Dev A; Gastroenterology, Monash Health, Melbourne, Australia.
Paul E; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Cheung W; Radiology, Alfred Health, Melbourne, Australia.
Koukounaras J; Radiology, Alfred Health, Melbourne, Australia.
Jhamb A; Radiology, St. Vincent's Hospital, Melbourne, Australia.
Marginson B; Radiology, St. Vincent's Hospital, Melbourne, Australia.
Lim BG; Radiology, Royal Melbourne Hospital, Melbourne, Australia.
Simkin P; Radiology, Royal Melbourne Hospital, Melbourne, Australia.
Borsaru A; Radiology, Monash Health Eastern Health, Melbourne, Australia.
Burnes J; Radiology, Monash Health Eastern Health, Melbourne, Australia.
Goodwin M; Radiology, Austin Health, Melbourne, Australia.
Ramachandra V; Radiology, Eastern Health, Melbourne, Australia.
Spanger M; Radiology, Eastern Health, Melbourne, Australia.
Lubel J; Department of Gastroenterology, The Alfred Hospital, 55 Commercial Rd, Melbourne, 3004, Australia.
Gow P; Gastroenterology, Austin Health, Melbourne, Australia.
Sood S; Gastroenterology, Royal Melbourne Hospital, Melbourne, Australia.
Thompson A; Gastroenterology, St. Vincent's Hospital, Melbourne, Australia.
Ryan M; Gastroenterology, St. Vincent's Hospital, Melbourne, Australia.
Nicoll A; Gastroenterology, Eastern Health, Melbourne, Australia.
Bell S; Gastroenterology, Monash Health, Melbourne, Australia.
Majeed A; Department of Gastroenterology, The Alfred Hospital, 55 Commercial Rd, Melbourne, 3004, Australia.
Kemp W; Department of Gastroenterology, The Alfred Hospital, 55 Commercial Rd, Melbourne, 3004, Australia.
Roberts SK; Department of Gastroenterology, The Alfred Hospital, 55 Commercial Rd, Melbourne, 3004, Australia. .
Pokaż więcej
Corporate Authors:
Melbourne Liver Group
Źródło:
BMC cancer [BMC Cancer] 2020 May 29; Vol. 20 (1), pp. 483. Date of Electronic Publication: 2020 May 29.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Carcinoma, Hepatocellular/*therapy
Chemoembolization, Therapeutic/*methods
Liver Neoplasms/*therapy
Neoplasm Recurrence, Local/*therapy
alpha-Fetoproteins/*analysis
Aged ; Australia/epidemiology ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/mortality ; Chemoembolization, Therapeutic/adverse effects ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/blood ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/mortality ; Patient Selection ; Prognosis ; Retreatment/adverse effects ; Retreatment/methods ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Autorzy:
Fumet JD; Department of Medical Oncology, Center GF Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France. .; Research Platform in Biological Oncology, Dijon, France. .; GIMI Genetic and Immunology Medical Institute, Dijon, France. .; University of Burgundy-Franche Comté, Dijon, France. .; UMR INSERM 1231, Dijon, France. .
Limagne E; Research Platform in Biological Oncology, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Thibaudin M; Research Platform in Biological Oncology, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Truntzer C; Research Platform in Biological Oncology, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Bertaut A; Department of Epidemiology and Biostatistics, Georges François Leclerc Center, Dijon, France.
Rederstorff E; Department of Epidemiology and Biostatistics, Georges François Leclerc Center, Dijon, France.
Ghiringhelli F; Department of Medical Oncology, Center GF Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France.; Research Platform in Biological Oncology, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Aug 10; Vol. 20 (1), pp. 748. Date of Electronic Publication: 2020 Aug 10.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Mutation*
Neoplasms*/drug therapy
Neoplasms*/genetics
Precision Medicine*/methods
Recombinational DNA Repair*/genetics
Female ; Humans ; Male ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Immunotherapy/methods ; Phthalazines/administration & dosage ; Piperazines/administration & dosage ; Progression-Free Survival ; Prospective Studies ; Retreatment ; Clinical Trials, Phase II as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term outcomes and significance of preoperative lymphocyte-to-monocyte ratio as a prognostic indicator in patients with invasive pancreatic neoplasms after repeat pancreatectomy.
Autorzy:
Takano S; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Yoshitomi H; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Kagawa S; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Furukawa K; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Takayashiki T; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Kuboki S; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Suzuki D; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Sakai N; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Mishima T; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Nakadai E; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Miyazaki M; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan.
Ohtsuka M; Department of General Surgery, Chiba University, Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba, 260-8677, Japan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Feb 10; Vol. 20 (1), pp. 111. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji:
Journal Article
MeSH Terms:
Leukocyte Count*
Lymphocytes*
Monocytes*
Pancreatic Neoplasms/*blood
Pancreatic Neoplasms/*mortality
Aged ; Biomarkers ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Invasiveness ; Pancreatectomy ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/surgery ; Preoperative Period ; Prognosis ; Recurrence ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.
Autorzy:
Connell CM; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.; Department of Oncology, CRUK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Brais R; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Whitaker H; Research Department for Tissue & Energy, Division of Surgery & Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.
Upponi S; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Beh I; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Risdall J; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Corrie P; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Janowitz T; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.; Department of Oncology, CRUK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK.
Jodrell DI; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK. .; Department of Oncology, CRUK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Jan 15; Vol. 20 (1), pp. 38. Date of Electronic Publication: 2020 Jan 15.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Gene Expression*
Antimetabolites, Antineoplastic/*therapeutic use
Carcinoma, Adenosquamous/*drug therapy
Carcinoma, Adenosquamous/*genetics
Cytidine Deaminase/*genetics
Deoxycytidine/*analogs & derivatives
Pancreatic Neoplasms/*drug therapy
Pancreatic Neoplasms/*genetics
Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Carcinoma, Adenosquamous/diagnosis ; Chemotherapy, Adjuvant ; Cytidine Deaminase/metabolism ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/therapeutic use ; Female ; Humans ; Immunohistochemistry ; Magnetic Resonance Imaging ; Middle Aged ; Pancreatic Neoplasms/diagnosis ; Pancreatic Neoplasms/mortality ; Recurrence ; Retreatment ; Tomography, X-Ray Computed ; Treatment Outcome ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Autorzy:
Guo X; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Zhao F; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Ma X; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Shen G; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Ren D; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Zheng F; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.; Shouguang Hospital of Traditional Chinese Medicine, Weifang, 262700, China.; Department of Medical Oncology, Cancer hospital, Chinese academy of medical sciences, Peking Union Medical College, Beijing, 100021, China.
Du F; Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Wang Z; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Ahmad R; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Yuan X; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Zhao J; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China. .
Zhao J; Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Nov 20; Vol. 19 (1), pp. 1125. Date of Electronic Publication: 2019 Nov 20.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*mortality
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Male ; Neoplasm Metastasis ; Neoplasm Staging ; Odds Ratio ; Publication Bias ; Retreatment ; Stomach Neoplasms/diagnosis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
Autorzy:
Sun J; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Zhang T; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Wang J; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Li W; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Zhang A; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
He W; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Zhang D; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Li D; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Ding J; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China.
Duan X; Radiation Oncology Center, The Fifth Medical Center of PLA General Hospital (Beijing 302 Hospital), No. 100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Aug 28; Vol. 19 (1), pp. 846. Date of Electronic Publication: 2019 Aug 28.
Typ publikacji:
Journal Article
MeSH Terms:
Radiosurgery*/adverse effects
Radiosurgery*/methods
Radiotherapy Dosage*
Carcinoma, Hepatocellular/*pathology
Carcinoma, Hepatocellular/*radiotherapy
Liver Neoplasms/*pathology
Liver Neoplasms/*radiotherapy
Adult ; Aged ; Biomarkers, Tumor ; Carcinoma, Hepatocellular/mortality ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Radiation Injuries/diagnosis ; Radiation Injuries/etiology ; Recurrence ; Retreatment ; Treatment Outcome ; Tumor Burden
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Salvage PRRT with Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.
Autorzy:
Rudisile S; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Gosewisch A; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Wenter V; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Unterrainer M; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Böning G; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Gildehaus FJ; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Fendler WP; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.; Department of Nuclear Medicine, University Hospital, University of Essen, Essen, Germany.
Auernhammer CJ; Department of Internal Medicine 4, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), LMU Munich, Munich, Germany.
Spitzweg C; Department of Internal Medicine 4, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), LMU Munich, Munich, Germany.
Bartenstein P; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), LMU Munich, Munich, Germany.
Todica A; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), LMU Munich, Munich, Germany.
Ilhan H; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. .; ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), LMU Munich, Munich, Germany. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Aug 08; Vol. 19 (1), pp. 788. Date of Electronic Publication: 2019 Aug 08.
Typ publikacji:
Journal Article
MeSH Terms:
Coordination Complexes/*therapeutic use
Neuroendocrine Tumors/*radiotherapy
Octreotide/*analogs & derivatives
Radiopharmaceuticals/*therapeutic use
Aged ; Aged, 80 and over ; Combined Modality Therapy ; Coordination Complexes/administration & dosage ; Coordination Complexes/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neuroendocrine Tumors/diagnosis ; Neuroendocrine Tumors/metabolism ; Neuroendocrine Tumors/mortality ; Octreotide/administration & dosage ; Octreotide/adverse effects ; Octreotide/therapeutic use ; Positron Emission Tomography Computed Tomography ; Radiation Dosage ; Radiometry ; Radiopharmaceuticals/adverse effects ; Receptors, Peptide/metabolism ; Retreatment ; Salvage Therapy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
Autorzy:
da Costa AABA; Department of Medical Oncology, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, CEP: 01509-010, Brazil. .
do Canto LM; CIPE - AC Camargo Cancer Center, São Paulo, Brazil.; Dept of Clinical Genetics, Vejle Hospital, Institute of Regional Health Research, University of Southern Denmark, Vejle, DK, Denmark.
Larsen SJ; Dept of Mathematics and Computer Science, University of Southern Denmark, Odense, DK, Denmark.
Ribeiro ARG; Department of Medical Oncology, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, CEP: 01509-010, Brazil.
Stecca CE; Department of Medical Oncology, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, CEP: 01509-010, Brazil.
Petersen AH; Dept of Mathematics and Computer Science, University of Southern Denmark, Odense, DK, Denmark.
Aagaard MM; Dept of Mathematics and Computer Science, University of Southern Denmark, Odense, DK, Denmark.
de Brot L; Dept of Pathology, AC Camargo Cancer Center, São Paulo, Brazil.
Baumbach J; Chair of Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan Technical University of Munich, Munich, Germany.
Baiocchi G; Dept of Gynecologic Oncology, AC Camargo Cancer Center, São Paulo, Brazil.
Achatz MI; Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, Brazil.
Rogatto SR; Dept of Clinical Genetics, Vejle Hospital, Institute of Regional Health Research, University of Southern Denmark, Vejle, DK, Denmark.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 May 06; Vol. 19 (1), pp. 422. Date of Electronic Publication: 2019 May 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Cyclin E/*genetics
Drug Resistance, Neoplasm/*genetics
Oncogene Proteins/*genetics
Ovarian Neoplasms/*genetics
Platinum Compounds/*pharmacology
Retinoblastoma Binding Proteins/*genetics
Ubiquitin-Protein Ligases/*genetics
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brazil/epidemiology ; Child, Preschool ; DNA Copy Number Variations/genetics ; DNA Mutational Analysis ; Female ; Homologous Recombination/genetics ; Humans ; Middle Aged ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/mortality ; Platinum Compounds/therapeutic use ; Progression-Free Survival ; Retreatment ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
Autorzy:
Vickers AD; RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK. .
Winfree KB; Eli Lilly and Company Limited, Indianapolis, IN, USA.
Cuyun Carter G; Eli Lilly and Company Limited, Indianapolis, IN, USA.
Kiiskinen U; Eli Lilly and Company Limited, Helsinki, Finland.
Jen MH; Eli Lilly and Company Limited, Windlesham, Surrey, UK.
Stull D; RTI Health Solutions, Research Triangle Park, NC, USA.
Kaye JA; RTI Health Solutions, Waltham, MA, USA.
Carbone DP; Ohio State University Medical Center, Columbus, OH, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Apr 15; Vol. 19 (1), pp. 353. Date of Electronic Publication: 2019 Apr 15.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*therapy
Lung Neoplasms/*therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/etiology ; Carcinoma, Non-Small-Cell Lung/mortality ; Disease Management ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/etiology ; Lung Neoplasms/mortality ; Molecular Targeted Therapy ; Prognosis ; Proportional Hazards Models ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Autorzy:
Iguchi T; Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. .
Tamada S; Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Kato M; Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Yasuda S; Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Yamasaki T; Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Nakatani T; Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Apr 11; Vol. 19 (1), pp. 339. Date of Electronic Publication: 2019 Apr 11.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Clinical Protocols*
Flutamide/*therapeutic use
Phenylthiohydantoin/*analogs & derivatives
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzamides ; Flutamide/administration & dosage ; Flutamide/adverse effects ; Humans ; Male ; Nitriles ; Phenylthiohydantoin/administration & dosage ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Research Design ; Retreatment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study.
Autorzy:
Zhang W; Department of Ultrasound, Beijing Tian Tan Hospital, Capital Medical University, No. 119, West Road of South 4th Ring Road, Fengtai District, Beijing, 100160, China.
Jin ZQ; Department of Ultrasound, Affiliated Hospital of Guilin Medical University, Guilin, China.
Baikpour M; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Li JM; Department of Ultrasound, The 3rd Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhang H; Department of Thyroid and Breast Surgery, The 3rd Affiliated Hospital of Guangxi Medical University, Nanning, China.
Liang T; Department of Ultrasound, The 3rd Affiliated Hospital of Guangxi Medical University, Nanning, China.
Pan XM; Department of Thyroid and Breast Surgery, The 3rd Affiliated Hospital of Guangxi Medical University, Nanning, China.
He W; Department of Ultrasound, Beijing Tian Tan Hospital, Capital Medical University, No. 119, West Road of South 4th Ring Road, Fengtai District, Beijing, 100160, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Apr 11; Vol. 19 (1), pp. 345. Date of Electronic Publication: 2019 Apr 11.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms/*therapy
Microwaves/*therapeutic use
Radiofrequency Ablation/*methods
Adolescent ; Adult ; Aged ; Biopsy ; Breast/diagnostic imaging ; Breast/pathology ; Breast/radiation effects ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/pathology ; Feasibility Studies ; Female ; Follow-Up Studies ; Humans ; Male ; Microwaves/adverse effects ; Middle Aged ; Prospective Studies ; Radiofrequency Ablation/adverse effects ; Retreatment/statistics & numerical data ; Treatment Outcome ; Ultrasonography, Interventional ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Autorzy:
Wang J; Department of Radiation Oncology, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China.
Chen J; Department of Medical Oncology, Quzhou People's Hospital, No. 2 Zhongloudi Road, Quzhou, 324000, People's Republic of China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Feb 08; Vol. 19 (1), pp. 131. Date of Electronic Publication: 2019 Feb 08.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Alleles*
Mutation*
Adenocarcinoma of Lung/*drug therapy
Adenocarcinoma of Lung/*genetics
Antineoplastic Agents/*therapeutic use
Crown Ethers/*therapeutic use
Quinazolines/*therapeutic use
Acrylamides/therapeutic use ; Adenocarcinoma of Lung/diagnosis ; Aged ; Amino Acid Substitution ; Aniline Compounds/therapeutic use ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biomarkers ; Brain Neoplasms/diagnosis ; Brain Neoplasms/secondary ; Combined Modality Therapy ; Crown Ethers/administration & dosage ; Crown Ethers/adverse effects ; ErbB Receptors/genetics ; Humans ; Magnetic Resonance Imaging ; Male ; Neoplasm Metastasis ; Neoplasm Staging ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Retreatment ; Tomography, X-Ray Computed ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Autorzy:
Ito S; Department of Gastroenterological Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. .
Ohashi Y; Department of Integrated Science and Engineering for Sustainable Society, Chuo University, 1-13-27 Kasuga, Bunkyo-ku, Tokyo, 112-8551, Japan.
Sasako M; Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya City, Hyogo, 663-8501, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Apr 20; Vol. 18 (1), pp. 449. Date of Electronic Publication: 2018 Apr 20.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic/*therapeutic use
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*mortality
Tegafur/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Retreatment ; Stomach Neoplasms/pathology ; Survival Analysis ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial.
Autorzy:
Sandra-Petrescu F; Surgical Department, University Medical Centre Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. .
Herrle F; Surgical Department, University Medical Centre Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Burkholder I; Department of Nursing and Health, University of Applied Sciences of the Saarland, Goebenstr. 40, D-66117, Saarbruecken, Germany.
Kienle P; Surgical Department, University Medical Centre Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Hofheinz RD; Day Treatment Center (TTZ), Interdisciplinary Tumor Center Mannheim (ITM) & III Medical Clinic, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Apr 03; Vol. 18 (1), pp. 369. Date of Electronic Publication: 2018 Apr 03.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Rectal Neoplasms/*drug therapy
Rectal Neoplasms/*mortality
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Staging ; Rectal Neoplasms/pathology ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
Autorzy:
Pulido M; Clinical and Epidemiology Department & Clinical Investigation Center INSERM CIC 1401, Bergonié Institute, Bordeaux, France.
Roubaud G; Medical Oncology Department, Bergonié Institute, Bordeaux, France.
Cazeau AL; Nuclear Medicine Department, Bergonié Institute, Bordeaux, France.
Mahammedi H; Medical Oncology Department, Jean Perrin Cancer Center, Clermont-Ferrand, France.
Vedrine L; Hartmann Oncology Radiotherapy Group, Levallois-Peret, France.
Joly F; Medical Oncology Department, François Baclesse Cancer Center, Caen, France.
Mourey L; Medical Oncology Department, IUCT Oncopole, Toulouse, France.
Pfister C; Urology Department, Rouen University Hospital & Clinical Investigation Center INSERM CIC 1404, Rouen, France.
Goberna A; Clinical and Epidemiology Department & Clinical Investigation Center INSERM CIC 1401, Bergonié Institute, Bordeaux, France.
Lortal B; Medical Oncology Department, Bergonié Institute, Bordeaux, France.
Bellera C; Clinical and Epidemiology Department & Clinical Investigation Center INSERM CIC 1401, Bergonié Institute, Bordeaux, France.
Pourquier P; INSERM U1194, Montpellier Cancer Research Institute, Montpellier, France.
Houédé N; INSERM U1194, Montpellier Cancer Research Institute, Montpellier, France. .; Medical Oncology Department, Nimes University Hospital, Nimes, France. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Feb 17; Vol. 18 (1), pp. 194. Date of Electronic Publication: 2018 Feb 17.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Sirolimus/*analogs & derivatives
Urinary Bladder Neoplasms/*drug therapy
Urinary Bladder Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Retreatment ; Sirolimus/administration & dosage ; Sirolimus/adverse effects ; Sirolimus/therapeutic use ; Treatment Outcome ; Urinary Bladder Neoplasms/metabolism ; Urinary Bladder Neoplasms/mortality
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
Autorzy:
Yang L; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, China. .
Alyasova A; Prevoljskiy Region Medical Centre, Ilinskaua St, N, Novgorod, 603109, Russia.
Ye D; Fudan University Shanghai Cancer Center, 220 Handan Rd, Yangpu, Shanghai, China.
Ridolfi A; Novartis Pharma S.A.S, 2 Rue Lionel Terray, 92500, Rueil-Malmaison, France.
Dezzani L; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
Motzer RJ; Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Feb 17; Vol. 18 (1), pp. 195. Date of Electronic Publication: 2018 Feb 17.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Carcinoma, Renal Cell/*pathology
Everolimus/*therapeutic use
Kidney Neoplasms/*drug therapy
Kidney Neoplasms/*pathology
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Carcinoma, Renal Cell/mortality ; Everolimus/administration & dosage ; Everolimus/adverse effects ; Female ; Humans ; Kidney Neoplasms/mortality ; Male ; Neoplasm Metastasis ; Neoplasm Staging ; Retreatment ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Autorzy:
Sztankay M; Department of Psychiatry, Psychotherapy & Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria. .; Leopold-Franzens-University of Innsbruck, Innsbruck, Austria. .
Giesinger JM; Department of Psychiatry, Psychotherapy & Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.
Zabernigg A; Department of Internal Medicine, Kufstein County Hospital, Kufstein, Austria.
Krempler E; Department of Psychiatry, Psychotherapy & Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.
Pall G; Waldburg-Zeil Akutkliniken GmbH & Co. KG, Wangen, Germany.
Hilbe W; Department of Internal Medicine I (Haematology and Oncology), Wilhelminenspital Wien, Vienna, Austria.
Burghuber O; Respiratory Oncology Unit, Department of Respiratory and Critical Care Medicine, Otto-Wagner-Spital, Vienna, Austria.
Hochmair M; Respiratory Oncology Unit, Department of Respiratory and Critical Care Medicine, Otto-Wagner-Spital, Vienna, Austria.
Rumpold G; Department of Psychiatry, Psychotherapy & Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.
Doering S; Department of Psychoanalysis and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Holzner B; Department of Psychiatry, Psychotherapy & Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2017 Aug 23; Vol. 17 (1), pp. 565. Date of Electronic Publication: 2017 Aug 23.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Clinical Decision-Making*
Quality of Life*
Carcinoma, Non-Small-Cell Lung/*epidemiology
Carcinoma, Non-Small-Cell Lung/*psychology
Lung Neoplasms/*epidemiology
Lung Neoplasms/*psychology
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Combined Modality Therapy ; Female ; Health Care Surveys ; Humans ; Induction Chemotherapy ; Lung Neoplasms/drug therapy ; Maintenance Chemotherapy ; Male ; Neoplasm Staging ; Patient Preference ; Retreatment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 53

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies